BOSTON--(BUSINESS WIRE)--New clinical data on the hepatitis C polymerase inhibitor R1626 – currently in development by Roche – show viral reductions greater than those described for other polymerase inhibitors, according to data presented at the 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). These results were achieved in chronic hepatitis C patients infected with the difficult-to-treat genotype 1 virus.
